Surveillance of transmitted drug-resistant HIV among young pregnant women in Ouagadougou, Burkina Faso

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 4, 2012, Pages

  Somda, Antoine ^a   Sangare, Lassana ^b   Soro, Monique ^b   Yameogo, Saydou ^b   Bazie, Babou ^c   Bigirimana, Françoise ^c   Bertagnolio, Silvia ^c   Peeters, Martine ^d   Mouacha, Fatima ^e   Rivera, Ana Maria ^e   Jordan, Michael R ^c,e   Sanou, Marie Joseph ^a  

^a Ministry of Health/BFA   (Burkina Faso)

^b MINISTÈRE DE LA SANTÉ   (Burkina Faso)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITÉ DE MONTPELLIER   (France)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; BURKINA FASO; DISEASE SURVEILLANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MONITORING; PREGNANT WOMAN; PRENATAL CARE; PRIMIGRAVIDA; PRIORITY JOURNAL; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTI-RETROVIRAL AGENTS; BURKINA FASO; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; POPULATION SURVEILLANCE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; YOUNG ADULT;

EID: 84860366005     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir988     Document Type: Article

References (18)

1. Joint United Nations Program on HIV/AIDS. UNAIDS report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS, 2010. Available at: http://www.unaids.org/globalreport/documents/20101123-Global Report-full-en.pdf.Accessed 15 July 2011.
2. World Health Organization, Joint United Nations Program on HIV/AIDS, UNICEF. Towards Universal Access: scaling up priority HIV/AIDS interventions in the health sector. Geneva: World Health Organization, 2010. Available at: http://www.who.int/hiv/pub/2010 progressreport/en/index.html. Accessed 15 July 2011.
3. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13(Suppl 2):1-13. (Pubitemid 352019085)
4. Bennett DE, Myatt M, Bertagnolio, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13(Suppl 2):25-36. (Pubitemid 352019087)
5. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13(Suppl 2):15-23. (Pubitemid 352019086)
6. De Gruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiv Ther 2000; 5:41-8. (Pubitemid 30261205)
7. Hanna GJ, D'Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis 2001; 32:774-82. (Pubitemid 32221937)
8. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4:e4724.
9. Gifford RJ, Liu TF, Rhee SY, et al. The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 2009; 25:1197-8.
10. Vergne L, Diagbouga S, Kouanfack C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther 2006; 11:575-9. (Pubitemid 44277422)
11. Dagnra AY, Vidal N, Niama FR, Prince-David M, Delaporte E, Peeters M. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients. Infect Genet Evol 2009; 9:646-52.
12. Ayouba A, Lien TT, Nouhin J, et al. Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Cô te d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study. AIDS Res Hum Retroviruses 2009; 25:1193-6.
13. Somi GR, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 2008; 13(Suppl 2):77-82. (Pubitemid 352019092)
14. Kamoto K, Aberle-Grasse J. Malawi HIV Drug Resistance Task Force. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 2008; 13(Suppl 2):83-7. (Pubitemid 352019093)
15. Abegaz WE, Grossman Z, Wolday D, et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther 2008; 13(Suppl 2):89-94. (Pubitemid 352019094)
16. Maphalala G, Okello V, Mndzebele S, et al. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther 2008; 13(Suppl 2):95-100. (Pubitemid 352019095)
17. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13(Suppl 2):101-7. (Pubitemid 352019096)
18. Jordan MR, Parkin N, Bertagnolio S. Surveillance of transmitted and acquired HIV drug resistance using World Health Organization survey methods in resource limited settings. Antivir Ther 2011; 16(Suppl 1):A41. ZZ